Last reviewed · How we verify

NCT03190850: MARITSA

Effect of Inspiratory Muscle Training

Status unknown NA Last updated 19 June 2017
What this trial tests

NA trial testing Intervention in Sleep Apnea, Obstructive in 30 participants. Status unknown.

Timeline
5 April 2016
Primary endpoint
9 March 2018
10 May 2018

Quick facts

Lead sponsorHospital de Clinicas de Porto Alegre
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date5 April 2016
Primary completion9 March 2018
Estimated completion10 May 2018
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Hospital de Clinicas de Porto Alegre

Who can join

Adults 65 to 80, any sex, with Sleep Apnea, Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effect of inspiratory muscle training on sleep apnea in the elderly. The patients screened will be randomized and allocated into two groups, intervention and control. In the intervention group, the patients will perform the exercises with the inspiratory muscular training apparatus called Powerbreathe with progressive load, according to its inspiratory muscular force. The control group will perform the same exercises, with the same apparatus, but without load.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Sleep Apnea, Obstructive

Currently open trials in the same condition.

Other Hospital de Clinicas de Porto Alegre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing